Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Insider. Direct buy.
Statement of Changes in Beneficial Ownership (4)
Source: Edgar (US Regulatory)
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
DRISCOLL FREDERICK W2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE3. Date of Earliest Transaction (MM/DD/YYYY)
9/3/2021(Street)
FLORHAM PARK, NJ 07932(City) (State) (Zip)4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned1.Title of Security
(Instr. 3)2. Trans. Date2A. Deemed Execution Date, if any3. Trans. Code
(Instr. 8)4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)7. Nature of Indirect Beneficial Ownership (Instr. 4)CodeVAmount(A) or (D)PriceCommon Stock 9/3/2021 P 19417 A$1.0426 19417 D
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)1. Title of Derivate Security
(Instr. 3)2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)8. Price of Derivative Security
(Instr. 5)9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Reporting Owners
Reporting Owner Name / AddressRelationshipsDirector10% OwnerOfficerOtherDRISCOLL FREDERICK W
C/O CELLECTAR BIOSCIENCES, INC.
100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932X
Signatures
/s/ Christina Blakley, attorney-in-fact for Frederick Driscoll9/7/2021**Signature of Reporting PersonDate
Or maybe trying to their price back up.
Statement of Changes in Beneficial Ownership (4)
Source: Edgar (US Regulatory)
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
1. Name and Address of Reporting Person *
Swirsky Douglas J2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last) (First) (Middle)
C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE3. Date of Earliest Transaction (MM/DD/YYYY)
6/30/2021(Street)
FLORHAM PARK, NJ 07932(City) (State) (Zip)4. If Amendment, Date Original Filed (MM/DD/YYYY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned1.Title of Security
(Instr. 3)2. Trans. Date2A. Deemed Execution Date, if any3. Trans. Code
(Instr. 8)4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)7. Nature of Indirect Beneficial Ownership (Instr. 4)CodeVAmount(A) or (D)Price
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)1. Title of Derivate Security
(Instr. 3)2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)8. Price of Derivative Security
(Instr. 5)9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of SharesStock option (right to buy) $1.19 6/30/2021 A 117000 (1)6/30/2031 Common Stock 117000 $0 117000 D
Explanation of Responses:(1) This option shall vest on the first anniversary of the date of grant.
Reporting Owners
Reporting Owner Name / AddressRelationshipsDirector10% OwnerOfficerOtherSwirsky Douglas J
C/O CELLECTAR BISCIENCES, INC.
100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932X
Signatures
/s/ Christina Blakley, attorney-in-fact for Douglas J. Swirsky7/2/2021**Signature of Reporting PersonDate
perhaps they are trying to avoid delisting-this won't work LOL!
Over $1 after hours.
Looks like a idiot was buying some stock today or should i say a sucker is born every min LOL> PT BARdum rules.
What's going on here?
14 days now below a dollor,soon a reverse in the plans to make sure this garbage stays listed paying off fee's for Crooked NASD who allows these scams.
Fake company developing nothing, but money to pay for a fancy office in NJ for a over weight CEO.
Drip Drip Drip-a frog won't jump out of hot water till it croaks. Same thing here with investor dollors.
company does nothing but steal your money-legalized crime
Peice of garbage-Lose money buy this.
Not so good............
If you left your money in this stock for years it would be more like 75%+. How do you feel about three or four reverses over the years?
Half - that's not so bad.........
Get ready for company steal half your money!
below a dollar-NASD letter out warning of delisting LOL!
When the stock goes below a dollar, CLRB has to get the price back up or get delisted. This shouldn't be allowed as it screws over bagholders-investors and lets bad company fake they are a real company. NASD doesn't care at all about investors only about collecting fee's from them. Investors often losses half their money
Can you please clarify what you mean by that?
Since you don't invest in the market,
it shouldn't bother you.
Strange that you post here day in day out though.
Besides, I flipped this for a couple ticks. So I did profit.
Only strange thing is:
2021-03-04Caruso James V (President and CEO) Buy5,100. 1.70
What do you think?
How can you believe anything coming from this company-it hasn't made anything at all that makes any money at all except from investor's most of which lost everything when they reverse the stock just to stay listed.
I don't invest in stocks any more,too many scams. Who needs these clowns.
I don't invest in stocks any more,too many scams. Who needs these clowns.
Yup, this looked like a no-brainer @ 1.03
I'm out at 1.10. Might be too early but, I'll take the flip. Will keep an eye on this.
Good luck.
But move on, bashing your losers isn't going to help you in any way.
Keep looking for winners.
fat ceo got a fancy office in NJ and then farm out a phony Canadian company to make its test drugs-it didn't work. 100% fraud. the founders have long since left the company leaving a brief case company now in NJ doing nothing but making false promises.
The company has several drugs in the pipeline and is trading at cash value! Decent institutional holders and I believe is listed on the Russel Index!
No,just reverse coming steal whats left of bag holders.
Hasn't that cheap, tawdry Ukrainian mail-order bride leeched the last nickel yett?
Won't be long.
LOL! Yeah, just like in CDEX, GLTC, ATMH, and TRON and all the other losers that losers buy.
Dump every share-tomorrow much worse!
almost below a dollar-reverse time LOL!
shorty happy today, tomorrow even better
when it breaks $1.00,watch yourdough get cuthalf.
sink all your money into ths stock its good for insiders need more dough. This is a breifcase stock if you know what that is. Just a bunch of worthless paper ??.
a reverse is going to happen very soon. Any bag holders will lose a lot of money. Must be getting desperate. Some no name company in south Korea. The only one who ever made money here is the insider's who paid next to nothing for the shares thast sell every time any type of news comes out.
Cellectar Biosciences inks collaboration agreement with South Korea's LegoChemBio
Source: Seeking Alpha
To read the full story on Seeking Alpha, click here.
Cash works wonder doesn't it!
Why Are Analysts Bullish About Penny Stock Cellectar Biosciences?
Source: TipRanks
Cellectar Biosciences (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company, focused on the development and discovery of drugs that can be used for the treatment of cancer. The company intends to use its proprietary Phospholipid Drug Conjugate (PDC) platform to develop PDCs that can specifically target cancer cells. The company’s drug pipeline includes CLR 131, one preclinical PDC chemotherapeutic program called CLR 1900, and several partnered PDC assets. Q1 Results Cellectar Biosciences had cash and cash equivalents of $53.6 million on its balance sheet as of March 31. While the company did not earn any revenues in Q1, the net loss was $0.13 per share versus a loss of $0.
https://www.tipranks.com/news/article/why-are-analysts-bullish-about-penny-stock-cellectar-biosciences
Followers
|
122
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
8169
|
Created
|
08/01/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |